AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 29 analysts
Fundamentals
Fundamentals institutional score is 75 using growth durability 74.6.
Valuation
Valuation institutional score is 19 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 61 using mean target upside 9.4%; dispersion penalty 15.2; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 80 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 1 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and technical structure provide support, while valuation and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 52.3% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.18). Confidence: 76%.
Live forward EPS implies next-12-month EPS of ₹93.70. Applying the stock's normalized valuation corridor produces a fair range of ₹3,950.39 to ₹5,473.95, with base value near ₹4,843.35 (-1.6% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹93.70
Forward P/E
52.5x
Base Fair Value
₹4,843.35
Fair Range
₹3,950.39 - ₹5,473.95
Upside To Base
-1.6%
Estimate Source
Live forward EPS
Growth Estimate
-8.2%
5Y Average
41.60
Current
78.75
Overvalued
58.42
Undervalued
42.16
5Y Average
20.69
Current
39.16
Overvalued
26.96
Undervalued
11.88
5Y Average
6.29
Current
11.91
Overvalued
8.20
Undervalued
3.61
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Fair | -12% vs avg | -2.7% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 19.0x Undervalued | -53% vs avg | +21.5% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.4x Premium | +128% vs avg | +121.8% |
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.9x Fair | -15% vs avg | +10.6% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Fair | -12% vs avg | +11.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Fair | -6% vs avg | -15.6% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Fair | -4% vs avg | +31.7% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.2x Undervalued | -27% vs avg | -3.9% |
TORRENT PHARMACEUTICALS L trades at a premium (78.7x vs peer avg 40.1x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include CIPLA LTD, LUPIN LIMITED, LAURUS LABS LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹2.60K CrDec 2025Latest net profit
₹587 CrDec 2025Latest EPS
₹17.04Dec 2025Net margin
30.8%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,920 | 2,121 | 2,146 | 2,123 | 2,143 | 2,438 | 2,434 | 2,377 | 2,433 | 2,616 | 2,762 | 2,599 |
| Expenses | 1,342 | 1,384 | 1,410 | 1,433 | 1,427 | 1,539 | 1,520 | 1,490 | 1,565 | 1,642 | 1,717 | 1,607 |
| Operating Profit | 396 | 554 | 544 | 499 | 521 | 710 | 724 | 696 | 678 | 787 | 856 | 801 |
| OPM % | 20.62% | 26.12% | 25.35% | 23.5% | 24.31% | 29.12% | 29.75% | 29.28% | 27.87% | 30.08% | 30.99% | 30.82% |
| Other Income | 26 | 11 | 15 | — | 76 | 21 | — | 3 | 15 | — | — | — |
| Interest | 94 | 90 | 77 | 69 | 67 | 64 | 54 | 48 | 47 | 45 | 37 | 34 |
| Depreciation | 182 | 183 | 192 | 191 | 195 | 189 | 190 | 191 | 190 | 187 | 189 | 191 |
| Profit before tax | 328 | 475 | 482 | 430 | 530 | 667 | 670 | 651 | 646 | 742 | 819 | 767 |
| Tax % | 33.23% | 32% | 32.16% | 30.93% | 22.64% | 29.69% | 31.34% | 25.5% | 22.91% | 25.74% | 25.52% | 23.47% |
| Net Profit | 219 | 323 | 327 | 297 | 410 | 469 | 460 | 485 | 498 | 551 | 610 | 587 |
| EPS in Rs | 6.46 | 9.55 | 9.65 | 8.78 | 12.12 | 13.86 | 13.60 | 14.33 | 14.00 | 16.28 | 17.64 | 17.04 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.